Latest From Bonti Inc.
While AbbVie said its $63bn purchase places little value on Allergan's R&D pipeline, the companies have 62 drugs in clinical development with 38 in Phase II and III or filed with regulators, including new indications for approved products.
2018 was a banner year for venture funding, and Relay's December Series C was only the third largest VC round of the year. Other year-end financings include Millendo, Erasca, Aristea and more...
Lim, CEO of Ignyta when it was sold to Roche earlier this year, has moved on to the start-up Erasca with $42m in Series A venture cash to develop "precision oncology" drugs.
Medical aesthetics is a unique biopharmaceutical niche that may scare off companies due to the consumer marketing and doctor relationship-building skills needed to compete in this market, but the potential for growth keeps major players engaged and searching for new technology.
- Therapeutic Areas
- Neurology, Nervous System
- Endurance Biotech Inc.
- North America
- Company Type
- Parent & Subsidiaries
- Bonti Inc.
- Senior Management
Fauad Hasan, CEO
David Ramsay, CFO
Mike Jarpe, PhD, EVP, Drug Dev.
Wajdie Ahmad, COO
Susan Abushakra, MD, CMO
James Stonecypher, SVP, Quality & Reg.
- Contact Info
4921 Birch St
Newport Beach, CA 92660
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.